Description
IGF::OT::IGF 2000 MG OF PROLASTIN-C
First action · last action
2014-01-30 · 2014-06-05
Transactions
2
First transaction's obligation
$4,864
Base + all options value (sum of deltas)
$4,864
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797D30042
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2014-01-30+$4,864= $4,864
- Mod P000012014-06-05+$0= $4,864
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2014-01-30 | +$4,864 | $4,864 | IGF::OT::IGF 2000 MG OF PROLASTIN-C |
| Mod P00001· OTHER ADMINISTRATIVE ACTION | 2014-06-05 | +$0 | $4,864 | IGF::OT::IGF 2000 MG OF PROLASTIN-C |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI UFQ3A7GKJ5C7)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C26022F0140 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $100,282 | FY2022 |
| 36C26022F0004 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $454,461 | FY2022 |
| 36C26021F0264 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $130,406 | FY2021 |
| 36C26021F0117 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $75,000 | FY2021 |
| 36C26021F0014 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $220,000 | FY2021 |
| 36C26021F0021 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $355,273 | FY2021 |
Other recipients under 6505 from 693-WILKES-BARRE (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA25915F2536 | FISHER SCIENTIFIC COMPANY L.L.C. | 693-WILKES-BARRE | $15,879 | FY2015 |
| VA24414F1952 | MDD US OPERATIONS, LLC | 693-WILKES-BARRE | $108,000 | FY2014 |
| VA24414F1769 | MDD US OPERATIONS, LLC | 693-WILKES-BARRE | $9,000 | FY2014 |
| VA24414J0800 | JAZZ PHARMACEUTICALS, INC | 693-WILKES-BARRE | $37,081 | FY2014 |
| VA24414P0412 | TRIAD ISOTOPES, INC. | 693-WILKES-BARRE | $71,600 | FY2014 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24414J0959_3600_V797D30042_3600 · retrieved 2026-09-26.